Serological markers of inflammation as predictors of complications in patients undergoing high-dose chemotherapy with hematopoietic stem cell rescue autologous

• Grant number: 10/10109-1
• Support Opportunities: Regular Research Grants
• Start date: May 01, 2011
• End date: April 30, 2013
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Vladmir Cláudio Cordeiro de Lima
• Grantee: Vladmir Cláudio Cordeiro de Lima
• Host Institution: Hospital A C Camargo. Fundação Antonio Prudente (FAP). São Paulo , SP, Brazil
• Associated researchers: Luciane Nogueira Machado ; Ludmilla Thomé Domingos Chinen

Abstract

The use of high dose chemotherapy with hematopoietic stem cell rescue or bone marrow transplantation (BMT), is considered a successful treatment option for a wide variety of neoplastic, metabolic and immune diseases. However, complications such as infections, mucositis, diarrhea, respiratory failure and sepsis are frequent, contributing to increased mortality rates. The complications in autologous BMT are especially due to the direct action of conditioning chemotherapy on organs and systems. The high dose chemotherapy is toxic to all tissues with a high rate of cell division, and the release of cytokines resulting from this injury may be responsible for the pathogenesis of many of these complications, but this still needs further investigation. Many researchers have worked on trying to find markers for diagnosis and prognosis of complications after transplant, and they have demonstrated the potential benefit of monitoring the levels of acute phase proteins and cytokines. The aim of our study is to analyze the serum levels of IL-1 sIL1R, IL6, IL8, IL10, IL12, IL18, TNFA, sTNFR, PTX3, CRP, procalcitonin and IL17 and their relationship with the most frequent events after transplantation. It is necessary to identify groups of patients at risk for infectious or non-infectious complications pos-transplant and manage early major potential complications, resulting in improved outcomes of high-dose chemotherapy. We hope to contribute to the identification of such individuals through analysis of a cytokine profile that may have correlation with complications. (AU)